The Ratings Game: Drug maker ChemoCentryx shares rocket on blockbuster potential in rare autoimmune disease

admin 5 years ago No Comments

This post was originally published on this site

A set of conclusive findings from a late-stage clinical trial testing ChemoCentryx Inc.’s experimental vasculitis treatment surprised company executives and investors, who now say they are bullish on the sales and pipeline potential of avacopan.

Prev Article Next Article

Help Me Retire: I’m a 35-year-old father of four with $135,000 saved for retirement. We’ve always lived paycheck to paycheck. ‘What am I doing wrong?’

admin December 17, 2021

Key Words: Elon Musk uses one unflattering word to describe Porsche-driver Bill Gates

admin February 18, 2020

NewsWatch: Investors are right to reboot worries over trade, HSBC strategist says

admin January 15, 2020

Anthony Scaramucci: The American people need a lot more stimulus cash

admin April 9, 2020

Realtor.com: Trump-Owned Home in Palm Beach Now Renting for $2.5M a Year

admin May 26, 2022

Personal Finance Daily: COVID-19 long haulers may explain America’s labor shortage and why mortgage rates could soon turn volatile

admin February 3, 2022

About The Author

admin

in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

By signing up above you will receive the Daily Buzz Offers newsletter and 3rd party advertisements. Expect up to 5 messages per week from us. You can unsubscribe at any time at the bottom of any of our emails.

Related Posts

About The Author

admin